Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170726 | 0.89 | PIK3CD (0.42) | MTNR1AMTNR1BELANEPDE3BPDE3A | |
| SCHEMBL9163656 | 0.88 | PIK3CD (0.41) | MTNR1AMTNR1BPARP1ELANE | |
| L-697661 SCHEMBL29456987 | 0.85 | FABP4 (0.34) | HPGD | |
| L-697661 SCHEMBL599639 | 0.85 | FABP4 (0.34) | HPGD | |
| SCHEMBL9166348 | 0.83 | IDH1 (0.37) | PARP1 | |
| SCHEMBL9281450 | 0.83 | RAB9A (0.41) | SMN1; SMN2ELANE | |
| SCHEMBL9171193 | 0.82 | FABP4 (0.34) | — | |
| SCHEMBL29456981 | 0.78 | KMT2A (0.35) | HPGDSMN1; SMN2ELANE | |
| SCHEMBL6367001 | 0.78 | KMT2A (0.35) | HPGDSMN1; SMN2ELANE | |
| SCHEMBL9846239 | 0.77 | MEN1 (0.32) | HPGDPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0650362-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1995-05-03 | — | — | EP | claimed |
| WO-1994002154-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| EP-0577243-A2 | Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | claimed |
| WO-1993019785-A1 | RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION | MERCK & CO., INC. (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0484071-A2 | Synergism of HIV reverse transcriptase inhibitors | MERCK & CO. INC. (US) | 1992-05-06 | — | — | EP | claimed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0650362-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994002154-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0577243-A2 | Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1993019785-A1 | RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION | MERCK & CO., INC. (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0484071-A2 | Synergism of HIV reverse transcriptase inhibitors | MERCK & CO. INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |